| Bioactivity | ZZL-7 is a fast-onset antidepressant agent. ZZL-7 works by disrupting the interaction between the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus (DRN). ZZL-7 can cross the blood-brain barrier readily. ZZL-7 can be used for the research of major depressive disorder (MDD)[1]. |
| Invitro | ZZL-7 (1.0 μM; or 2 h) incubation of the cultured 293T cells transfected with nNOS and SERT, significantly decreases the SERT-nNOS complex level[1]. |
| In Vivo | ZZL-7 (10 mg/kg, intraperitoneally) causes significantly increases firing frequency of serotonergic neurons 2 hours after treatment in vivo electrophysiology in SERT-Cre mice. In wild-type mice, ZZL-7 reduces immobility time[1].Intragastric administration of ZZL-7 (10, 20, and 40 mg/kg; once) produces antidepressant-like behaviors dose dependently 2 hours after treatment[1]. ZZL-7 (10 mg/kg; intraperitoneal administration) reverses chronic unpredictable mild stress (CMS)-induced depressions behaviors 2 hours after treatment[1]. Animal Model: |
| Name | ZZL-7 |
| CAS | 99141-91-0 |
| Formula | C11H20N2O4 |
| Molar Mass | 244.29 |
| Appearance | Oil |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Nan Sun, et al. Design of fast-onset antidepressant by dissociating SERT from nNOS in the DRN. Science. 2022 Oct 28;378(6618):390-398. |